Business Wire

BURJEEL-MEDICAL-CITY

23.5.2023 16:25:25 CEST | Business Wire | Press release

Share
Burjeel Medical City Launches Advanced Gynecology Institute to Offer Complex Care Solutions for Women

Burjeel Medical City, the flagship facility of Burjeel Holdings, has launched an Advanced Gynecology Institute (AGI) designed to offer multidisciplinary healthcare solutions to women of all ages. The launch comes just months after the hospital joined hands with the globally renowned Franco-European Multidisciplinary Institute of Endometriosis Academy (IFEM Endo). Three specialized clinics of the hospital - Gynecological Oncology, IFEM Endo Middle East Clinic, and Complex Gynecology Care - will come under AGI.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230523005817/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

H.E. Dr. Maitha Bint Salem Al Shamsi, Minister of State, UAE Government, inaugurating Advanced Gynecology Institute at Burjeel Medical City (Photo: AETOSWire)

Prof. Horace Roman, a renowned endometriosis surgeon and founding member of IFEM Endo, will be heading the institute. Dr. Benjamin Merlot, Consultant - Obstetrics and Gynecology and founding member of IFEM Endo, Dr. Sandesh Kade, Specialist - Obstetrics and Gynecology, Dr. Monica Chauhan, Specialist - Obstetrics & Gynecology, and Dr. Jafaru Abu, Consultant Gynecological Oncology Surgery, are other members of the team.

“The institute's launch is a significant milestone in women’s healthcare in the region. Women’s health needs are diverse and complex, requiring a holistic approach to ensure that each patient receives personalized care that meets her specific needs,” said Prof. Roman, adding that the expert team will also be involved in clinical research and training.

AGI possesses state-of-the-art surgical suites with the latest technology, allowing for advanced procedures such as laparoscopic and robotic surgeries. In addition to treating gynecological cancers, AGI focuses on preserving reproductive function in patients, and improving the quality of life for patients with advanced or recurrent gynecological malignancies. The institute also offers highly advanced minimally invasive surgeries for endometriosis.

“The institute showcases our commitment to excellence and cements our position as a leader in complex care. With a focus on specialized clinics, and personalized care, the institute is poised to make a significant impact on the healthcare sector in the UAE and beyond,” said Mr. John Sunil, CEO, Burjeel Holdings.

About Burjeel Medical City

Burjeel Medical City is a 400-bed multi-specialty hospital and quaternary care center located in Abu Dhabi, UAE. It offers high-quality specialized treatment and complex care in over 40 adult and pediatric specialties, aided by state-of-the-art medical technology and an international team of experts. Find more information at https://www.burjeelmedicalcity.com/

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005817/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Manhattan Associates’ 2026 Unified Commerce Benchmark Reveals the High Price of Standing Still in Retail23.3.2026 13:30:00 CET | Press release

Leaders achieve up to 2X revenue growth, but only 7% of retailers are true unified commerce leaders Manhattan Associates Inc. (NASDAQ: MANH), today announced the findings of its 2026 Global Unified Commerce Benchmark for Specialty Retail, the industry’s most comprehensive assessment of how well retailers connect digital and physical experiences to drive growth, profitability and loyalty. Conducted by Incisiv, a leading retail research firm, the Benchmark is based on real-world purchases and returns. It analyzes more than 400 specialty retailers across EMEA, LATAM and North America on 330 capabilities spanning four key experience areas: Shopping, Checkout, Fulfillment, and Service. The 2026 Benchmark reveals that while the industry has made steady progress in unified commerce maturity since 2023 when it was first launched, only 7% of retailers have achieved true unified commerce leadership while 33% are still stuck in the Basic category. Leaders are translating connected, data‑driven ye

Starr Completes Acquisition of IQUW Group23.3.2026 13:00:00 CET | Press release

Creates a stronger, more diversified global specialty platform Starr, a global investment and insurance organization, today announced that it has completed its acquisition of IQUW Group, creating a broader, more diversified specialty (re)insurance platform with enhanced capabilities across the London market, Bermuda and UK retail motor. The combined Starr business now serves more clients and brokers in more specialist classes and market segments globally. With IQUW Group, Starr has strengthened its position in the London market and established its managing agency as the ninth-largest at Lloyd’s. Importantly, Starr will continue to operate with a strong emphasis on underwriting expertise and best-in-class broker and client experience and service. Clients and brokers will benefit from a broader product offering, quick decision-making, greater capital strength and expanded global reach. Starr’s reinsurance capability is also significantly enhanced following this transaction. IQUW Re Bermu

Biocytogen Announces Strategic Collaboration with Moonlight Bio to Advance Cell Therapies Using Library of Antibody Binders23.3.2026 13:00:00 CET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic collaboration with Moonlight Bio, Inc., a Seattle-based biotech company pioneering advanced cell therapies. This partnership aims to develop cutting-edge cell therapies to address some of the most challenging and difficult-to-treat cancers. Dr. Yuelei Shen, President and CEO of Biocytogen, said, “We are thrilled to partner with Moonlight Bio, a pioneering leader in advanced cell therapies. This strategic collaboration leverages our proprietary off-the-shelf fully human antibody library to accelerate the development of cutting-edge cell therapies for difficult-to-treat cancers. It also demonstrates the versatility and broad applicability of Biocytogen’s antibody discovery platforms beyond traditional drug modalities. By combining our expertise,

Venture Global Launches First Advertising Campaign: “Unstoppable Energy”23.3.2026 11:30:00 CET | Press release

New ad campaign narrated by Academy Award winner Billy Bob Thornton will air nationally in the U.S. Today, Venture Global, Inc. (NYSE: VG) is launching its first national advertising campaign – “Unstoppable Energy”. The seven-figure, year-long campaign includes national and local broadcast television spots, as well as out-of-home, print, and digital ad placements. The company is proud to have Academy-Award winner Billy Bob Thornton as the campaign voiceover. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323692879/en/ “Venture Global is excited to unveil our very first national advertising campaign, featuring the accomplished Billy Bob Thornton as its voice,” said Venture Global CEO Mike Sabel. “The Unstoppable Energy campaign portrays the roll-up-your-sleeves tenacity and innovation that drives our company every day. We are proud to introduce the ethos and story of the Venture Global brand across the U.S. as we grow into

Venture Global and Vitol Announce New LNG Purchase Agreement23.3.2026 11:00:00 CET | Press release

Today, Venture Global, Inc. (NYSE: VG) and Vitol announced the execution of a new, binding agreement for the purchase of approximately 1.5 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for five years commencing in 2026, to be supplied from Venture Global’s portfolio. “Global demand for flexible, reliable U.S. LNG is rapidly growing, and Venture Global is proud to work with premier LNG trading companies like Vitol to provide this critical supply to the market,” said Venture Global CEO Mike Sabel. “Thanks to our innovative model, we have the ability to provide our customers with short, medium, and long-term LNG supply, and this agreement is another important step in diversifying the tenor of our LNG portfolio.” “Vitol is delighted to be working with Venture Global, a leading producer and supplier of LNG to world markets,” said Pablo Galante Escobar, Global Head of LNG at Vitol. “LNG is important to many economies worldwide. Through this transacti

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye